
BACKGROUND Paravalvular leak (PVL) following surgical aortic valve replacement is associated with significant morbidity, including heart failure and transfusion-dependent haemolytic anaemia. Transcatheter device closure, in contrast to surgical treatment, is a well-recognized treatment option due to its safer complication and mortality profiles. However, regional data and local experience showed that most PVL closures were done using non-dedicated devices which are not purposefully engineered to meet its specific pathology and anatomical complexity. OBJECTIVE To evaluate the feasibility and demonstrate procedural outcome using the Occlutech PLD Occluder device, a dedicated PVL closure device. CASE SUMMARY A 52-year-old man with prior Stanford type A aortic dissection repair, and redo aortic arch replacement with bioprosthetic aortic valve replacement, presented with progressive dyspnoea and transfusion-dependent haemolytic anaemia. Echocardiography confirmed the presence of PVL which was successfully closed with transcatheter strategy, using an Occlutech PLD 61PLD8W Occluder. RESULTS The Occlutech PLD Occluder device was successfully deployed with satisfactory results leading to significant improvement in patient’s symptoms. CONCLUSION The usage of a dedicated PVL closure device yielded positive outcome in our early experience, and supports broader availability and further evaluation of dedicated PVL closure devices in this setting.
BACKGROUND This study evaluates the procedural success rates, operative learning curves, and post-procedural complications associated with the initial clinical adoption of left bundle branch area pacing (LBBAP) at a provincial cardiovascular tertiary-care center. METHODS This retrospective cohort study evaluated 56 consecutive patients with clinical indications for permanent pacemaker implantation who underwent left bundle branch area pacing (LBBAP) during the first year of institutional adoption (May 2024 to May 2025) at the tertiary cardiovascular center of Banphaeo General Hospital, Samut Sakhon, Thailand. Primary endpoints included procedural success rates, chronological trends in procedural duration evaluated across four consecutive quarters, and procedurerelated complications. RESULTS The cohort (median age 73.5 years; 55.4% female) presented with a high prevalence of non-communicable diseases (82.5%). Main indications were complete heart block (46.4%) and sick sinus syndrome (26.8%). Successful LBBAP capture—evidenced by a left ventricular activation time (LVAT) and a right bundle branch block morphology—was achieved in 85.7% of cases. Electrophysiological outcomes showed a significant reduction in mean QRS duration post-implantation (p < 0.001), with 89.5% of patients achieving a QRS duration < 130 ms. Chronological analysis revealed a clear operative learning curve; median procedural times steadily declined by 32.6%, from 95.0 minutes in Quarter 1 (n=14) to 65.0 minutes in Quarter 4 (n=14), alongside a narrowing of data variability. The overall complication rate was 1.8%, consisting of a single lead dislodgement 10 days postprocedure. CONCLUSION LBBAP demonstrates high procedural success and a favorable safety profile, with efficiency improving significantly through accumulated operator experience.
INTRODUCTION Ejection fraction (EF) is a powerful prognosticator for heart failure (HF). Acute heart failure (AHF) may either be new onset or acute decompensated heart failure (ADHF). Studies were inconsistent on the association of HF categorized by EF with mortality among AHF patients particularly ADHF. METHODS A retrospective cohort study of ADHF patients enrolled in the national Philippine Heart Association AHF registry was conducted. Patients with de novo HF were excluded. Binary logistic regression analysis was done. RESULTS From 1123 patients with AHF, 460 patients (41%) were diagnosed with ADHF. Heart failure reduced EF (HFrEF) was the most common classification (50%), followed by heart failure preserved EF (HFpEF 31%), and heart failure mildly reduced EF (HFmrEF 18%). The mean age was 56 years. Majority has no identifiable precipitating factors for decompensation. In-hospital mortality occurred in 11 patients (2.72%) with cardiovascular mortality as the major cause of death. On adjusted analysis, the odds of dying for HFrEF and HFmrEF was 7x (OR adj= 6.7; 95% CI 0.65-64.35) and 3x (OR adj=3.29 95% CI 0.15- 70.60) respectively compared to the odds of dying in HFpEF. However, this result was not statistically significant. CONCLUSION Although there was a trend for higher odds of dying for HFrEF and HFmrEF as compared to HFpEF, but the study did not show statistical significance.
Proximal cap ambiguity in chronic total occlusion (CTO) is associated with increased procedural complexity, lower success rates, longer procedure time and greater use of retrograde approaches. Conventional angiography makes it challenging for interventionists to accurately identify the entry point, easily misdirecting the GW into the subintimal space, leading to PCI failure. We reported a 45-year-old male with CTO of the mid left anterior descending artery (LAD) with an ambiguous proximal cap. We used a Ping-Pong technique with two guide catheters (GC)s and intravascular ultrasound (IVUS) was used to identify the proximal cap. Retrograde wiring was performed through an ipsilateral collateral from diagonal artery, successfully crossed the LAD CTO and externalized into the antegrade GC. Firstly, the rendezvous and “tip-in” method were used, followed by the kissing microcatheter (MC) and chasing wires technique, which successfully revascularized the CTO.
INTRODUCTION In patients presenting with acute coronary syndrome (ACS) STsegment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) is the preferred modality of reperfusion. However, these patients may also have multivessel coronary artery disease (CAD) on coronary angiography, which is associated with a higher risk of mortality. Current guidelines recommend complete revascularization in STEMI patients with multivessel CAD; however, this poses a high risk of major acute cardiovascular events (MACE). Other available reperfusion strategies include staged vessel revascularization. This meta-analysis aimed to determine whether staged vessel revascularization can be a better mode of reperfusion strategy in patients with STEMI with multivessel CAD. METHODS A comprehensive search of randomized controlled trials (RCT) was conducted with the use of staged versus immediate complete vessel revascularization in patients with STEMI. Outcome measures used to assess the effectiveness of these techniques were all-cause mortality, MACE, target vessel revascularization, and stent thrombosis. The analyses were performed using a fixed effect analysis model using the Mantel- Haenszel statistical method via Review Manager V5.4. RESULTS Five studies were included in the meta-analysis with 1,483 subjects analyzed. There was a 27% lower risk of all-cause mortality (RR 0.73 [95% CI: 0.42-1.29]), 8% lower risk for MACE (RR 0.92 [95% CI: 0.60-1.39]) and in target vessel revascularization (RR 0.92 [95% CI: 0.53-1.63]), and a 29% decreased risk for stent thrombosis of staged revascularization versus immediate complete revascularization (RR 0.71 [95% CI: 0.28-1.83]) CONCLUSION Staged and immediate complete vessel revascularization are the treatment strategies recommended for hemodynamically stable STEMI patients. The meta-analysis showed better clinical outcomes in the staged vessel revascularization than in immediate complete revascularization in terms of all-cause mortality, MACE, target vessel revascularization, and stent thrombosis. This study suggests that staged vessel revascularization is a preferable type of revascularization in patients presenting with STEMI with multivessel CAD.